Archive for July, 2015
As a nationally-managed, Cisco Gold Partner, NWN Corporation participates in Cisco’s Customer Satisfaction program. Cisco sends surveys to NWN customers throughout the year to assess their satisfaction with the services NWN provides. Twice a year, Cisco calculates the results from the prior 12 months. We have been very lucky and have been awarded this prestigious award for 14 years in a row! – See more at: http://www.nwnit.com/who-we-are/news/news-item/awarded-ciscos-highest-honor-14-years-in-a-row!
Awarded Cisco’s Highest Honor 14 Years in a Row!
As a nationally-managed, Cisco Gold Partner, NWN Corporation participates in Cisco’s Customer Satisfaction program. Cisco sends surveys to NWN customers throughout the year to assess their satisfaction with the services NWN provides. Twice a year, Cisco calculates the results from the prior 12 months. We have been very lucky and have been awarded this prestigious award […] »
This week, Advanced Practice Strategies (APS) released High Risk Abdominal Pain in the Emergency Department, the newest course in its education and analytics solution – GNOSIS for EMERGENCY MEDICINE (EM). The nation’s most widely used online learning platform in the high-risk areas of obstetrics and emergency medicine, GNOSIS provides personalized learning for doctors and nurses. GNOSIS for EM also includes High Risk Chest Pain in the Emergency Department and Effective Communication in the Emergency Department.
“In a fast-paced, high-pressure environment like the emergency department, it’s vital to expand foundational knowledge and also practice judgment,” said Bill Binder, MD, Director of Emergency Medicine at APS. “With GNOSIS, we uniquely train clinicians in both types of learning to improve patient safety and quality of care.”
In addition to delivering evidence-based learning content to emergency department clinicians, the platform uses aggregate assessment data to measure team proficiency and identify areas of risk. According to a recent study of emergency department claims by The Doctors Company, more than half of claims resulted from patient assessment issues, which included failure to provide differential diagnosis and failure to address abnormal findings. Learning content in GNOSIS for EM was developed to address these issues and, ultimately, avoid adverse events.
Focusing on the most common diagnoses and treatments, High Risk Abdominal Pain in the Emergency Departmentexamines triage and initial evaluation of undifferentiated abdominal pain, and then examines gynecologic emergencies, vascular emergencies, extraabdominal causes of abdominal pain, and inflammatory surgical emergencies. The course examines cognitive bias and its impact on the diagnosis of abdominal pain. Specific diseases covered include ectopic pregnancy, ovarian torsion, ruptured ovarian cysts, PID and tuboovarian abscesses, AAA, iliac, splenic and hepatic aneurysms, mesenteric ischemia and thrombosis of the hepatic and renal and ovarian veins, appendicitis, testicular torsion, diverticulitis, choleycystitis, and pancreatitis. Additionally, perforation of the intestines, as well as bowel obstruction and cecal and sigmoid volvulus are covered in the course.
“Clearly, doctors and nurses in the emergency department are challenged with a myriad of difficult and high-risk situations every day,” said APS CEO Russ Richmond, MD. “By understanding their needs and the challenges they face, we developed this new course in GNOSIS to impact their ability to deliver the best possible patient care.”
Advanced Practice Strategies Launches High Risk Abdominal Pain in the Emergency Department
This week, Advanced Practice Strategies (APS) released High Risk Abdominal Pain in the Emergency Department, the newest course in its education and analytics solution – GNOSIS for EMERGENCY MEDICINE (EM). The nation’s most widely used online learning platform in the high-risk areas of obstetrics and emergency medicine, GNOSIS provides personalized learning for doctors and nurses. GNOSIS […] »
ORLANDO, FL. – This week at the American Podiatric Medical Association (APMA) Annual Scientific Meeting, Organogenesis Inc. will launch its new PuraPly™ wound management products. This includes the launch of PuraPly Antimicrobial (PuraPly AM), the first Food and Drug Administration (FDA)-cleared purified collagen matrix with polyhexamethylene biguanide hydrochloride (PHMB) antimicrobial agent.
PuraPly and PuraPly AM are the latest additions to the Organogenesis portfolio of advanced wound-care products. Both products are FDA 510(k)-cleared Class II medical devices approved for acute and chronic wound management across a variety of wound types, including partial- and full-thickness wounds, pressure ulcers, surgical wounds, trauma wounds, venous and diabetic ulcers1.
Both PuraPly and PuraPly AM have been approved for pass-through reimbursement in the hospital outpatient setting by the Centers for Medicare and Medicaid Services (CMS). PuraPly AM will be presented by Dr. Jeffrey Karr, DPM, on Thursday, July 23 at noon ET during a scientific presentation at APMA titled, “Shifting the antimicrobial paradigm – a novel purified collagen and antimicrobial technology for wound management,” and information on both products will be available at Organogenesis’ booth (#903) during the conference.
“Organogenesis is excited to be advancing healing through new wound care technologies that serve unmet needs and are available across the spectrum of wound management and healing applications,” said Gary S. Gillheeney, Sr., President and Chief Executive Officer of Organogenesis Inc. “With the addition of the PuraPly wound management products to our portfolio, we now offer clinicians products to treat wounds immediately when they enter their wound centers. Importantly, with PuraPly Antimicrobial, physicians have a treatment option for wounds with a high degree of bioburden. The PuraPly products can be used on most wounds that clinicians see in their centers. For diabetic ulcer and venous leg ulcer wounds that are truly chronic and do not respond to wound management, Organogenesis offers our Apligraf and Dermagraft bioengineered living cell-based products, the only FDA-approved wound healing therapies in the ‘skin substitute’ class.”
When used within the first four weeks of treatment, PuraPly creates an optimal environment for wounds of varying depth, regardless of severity or duration. PuraPly comprises layers of inherently strong, purified and biocompatible natural collagen matrix. PuraPly AM is unique in that it combines purified collagen with PHMB which provides broad antimicrobial coverage, protecting against a wide range of bacteria that colonize wounds and can progress to biofilm formation and infection. PuraPly AM can reduce the bacterial load in the wound bed, which if not addressed, can negatively impact tissue repair and delay healing.
PuraPly AM and PuraPly are both available in a range of sizes, in order to meet the needs of a variety of wound types.
Having pioneered the field, Massachusetts-based Organogenesis Inc. is a world leading regenerative medicine company focused in the areas of bio-active wound healing and soft tissue regeneration. The company’s mission is to bring the medical marvel of regenerative medicine products to patients and to standardize their use in everyday medical care. For more information, visit www.organogenesis.com.
Organogenesis Launches New PuraPly™ Products at the APMA 2015 Annual Scientific Meeting
ORLANDO, FL. – This week at the American Podiatric Medical Association (APMA) Annual Scientific Meeting, Organogenesis Inc. will launch its new PuraPly™ wound management products. This includes the launch of PuraPly Antimicrobial (PuraPly AM), the first Food and Drug Administration (FDA)-cleared purified collagen matrix with polyhexamethylene biguanide hydrochloride (PHMB) antimicrobial agent. PuraPly and PuraPly AM […] »
Datawatch received top honors from a distinguished panel of CEOs, CIOs, VCs, analysts and theHealthcare Tech Outlook editorial board, who annually review the top companies in the healthcare analytics space, and select those at the forefront of tackling industry challenges.
The panel selected Datawatch because the company delivers solutions that allow healthcare CIOs to create smarter data infrastructures that are less error-prone. “Datawatch’s Managed Analytics Platform for the healthcare sector is designed to include and handle the entire data lifecycle chain. The platform provides the ability to acquire and prepare any type of data, through automated processes and then visualize it for greater business insights – all with the governance and compliance capabilities needed by IT – especially in data sensitive industries such as healthcare,” the magazine stated.
“Datawatch Corporation has continued to provide innovative solutions in Healthcare Analytics arena for quite some time thereby reinventing the current landscape. We are happy to showcase them this year due to their excellence in delivering best-of-breed technology-driven solutions,” said Alex D’souza, Managing Editor, Healthcare Tech Outlook. “Datawatch Corporation solutions continued to break new ground within the past year, benefiting its customers around the globe, and we’re excited to have them featured on our top companies list.”
Datawatch provides users with a unique all-inclusive approach to visual analytics – offering users not only sophisticated tools for self-service data preparation, but also the ability to visualize data in real-time. It is particularly well-suited for healthcare applications because it can track changes to data throughout the analytics process and allows data masking that redacts certain parts of the patient’s information like their Social Security Number, medical history and other details to ensure privacy and security. Datawatch also gives healthcare professionals the ability to acquire, transform and prepare Electronic Data Interchange data or PDF data to assist with revenue cycle management and clinical trial management.
“Our Managed Analytics Platform is all about addressing challenges that CIOs face in hospitals and other industries, with a keen focus on accelerating business outcomes,” said Dan Potter, chief marketing officer of Datawatch Corporation. “We are grateful that Healthcare Tech Outlook recognized our technological innovations.”
To read the full article, click here: www.datawatch.com/TopHealthcareSolutionProviders
About Datawatch Corporation
Datawatch Corporation (NASDAQ-CM: DWCH) provides the only Managed Analytics Platform that brings together self-service data preparation with visual data discovery. Its software bridges the gap between the ease that business user’s demand and the automation and governance needed by IT. Users can quickly discover key factors that improve their business by transforming data from multi-structured sources, as well as real-time streaming data, into visually rich analytic applications. Organizations of every size, worldwide use Datawatch products, including 93 of the Fortune 100. Datawatch is headquartered in Chelmsford, Massachusetts with offices in New York, London, Frankfurt, Stockholm, Singapore, Melbourne and Manila, and with partners and customers in more than 100 countries worldwide. Learn more at www.datawatch.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any such statements contained herein, including but not limited to those relating to product performance and viability, are based on current expectations, but are subject to a number of risks and uncertainties that may cause actual results to differ materially from expectations. The factors that could cause actual future results to differ materially from current expectations include the following: rapid technological change; Datawatch’s dependence on the introduction of new products and product enhancements and possible delays in those introductions; acceptance of new products by the market, competition in the software industry generally, and in the markets for next generation analytics in particular; and Datawatch’s dependence on its principal products, proprietary software technology and software licensed from third parties. Further information on factors that could cause actual results to differ from those anticipated is detailed in various publicly-available documents, which include, but are not limited to, filings made by Datawatch from time to time with the Securities and Exchange Commission, including but not limited to, those appearing in the Company’s Annual Report on Form 10-K for the year ended September 30, 2014 and Forms 10-Q for the quarters ending December 31, 2014 and March 31, 2015. Any forward-looking statements should be considered in light of those factors.
Healthcare Tech Outlook Names Datawatch One of Best Healthcare Analytics Platforms
Chelmsford, Mass.—Datawatch Corporation (NASDAQ-CM: DWCH), today announced it was named one of the “20 Most Promising Healthcare Analytics Solutions Providers” by Healthcare Tech Outlook magazine. Datawatch received top honors from a distinguished panel of CEOs, CIOs, VCs, analysts and theHealthcare Tech Outlook editorial board, who annually review the top companies in the healthcare analytics space, and select those at the […] »
Advanced Practice Strategies (APS) is today releasing Hypertensive Disorders in Pregnancy, the newest course in its education and analytics solution GNOSIS for OBSTETRICS (OB). GNOSIS for OB is the nation’s most widely-used online learning platform that focuses on the highest areas of risk in obstetrics including Fetal Assessment and Monitoring, Shoulder Dystocia, Obstetrical Hemorrhage, and now Hypertensive Disorders in Pregnancy. In addition to delivering evidence-based learning content to clinicians, the platform uses aggregate assessment data to measure proficiency among doctors and nurses in order to identify clinical areas of risk. Currently, nearly 15% of all OB clinicians use GNOSIS for their education and training strategies.
“We listen to our physicians and nurses,” said Dr. Sandhya Gardner, Chief Content Officer at APS. “We know there is a need among our clinicians to learn more about hypertensive disorders in pregnancy, especially in the wake of new standards. We developed this course to make sure our clinicians are better-prepared.”
Equipping clinicians with the most up-to-date guidelines and practices, the Hypertensive Disorders in Pregnancy (HDP) curriculum advances knowledge and critical thinking for reducing the rise in often-preventable adverse outcomes resulting from HDP. Both California Maternal Quality Care Collaborative (CMQCC) and American Congress of Obstetricians and Gynecologists (ACOG) recently published new and updated guidelines around diagnosis and management resulting from evidence-based studies and data. As a result, improved clinical outcomes have been linked to education and implementation of these practices of standard care.¬
The HDP course is designed for obstetricians and perinatal nurses who manage patients during the antepartum, intrapartum, and postpartum periods. The learning modules are focused on the new and updated 2013 guidelines, which cover classification & nomenclature; diagnostic criteria; and management guidelines.
“Our mission is to help clinicians achieve their highest potential,” said APS CEO Russ Richmond, MD. “Helping doctors and nurses improve their competency is fundamental to improving patient care and we are proud to be a trusted resource in reaching that shared goal.”
Advanced Practice Strategies Launches Hypertensive Disorders in Pregnancy The Fourth Course in GNOSIS for OB
Advanced Practice Strategies (APS) is today releasing Hypertensive Disorders in Pregnancy, the newest course in its education and analytics solution GNOSIS for OBSTETRICS (OB). GNOSIS for OB is the nation’s most widely-used online learning platform that focuses on the highest areas of risk in obstetrics including Fetal Assessment and Monitoring, Shoulder Dystocia, Obstetrical Hemorrhage, and […] »